Censi Simona, Salmaso Laura, Ceccato Filippo, Manso Jacopo, Fedeli Ugo, Saia Mario, Mian Caterina
Endocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Clinical Governance Unit, Azienda Zero, Veneto Region, Italy.
Endocr Connect. 2023 Nov 14;12(12). doi: 10.1530/EC-23-0292. Print 2023 Dec 1.
An improvement in iodine status in Veneto Region has been documented in the last decade. We aimed at estimating the incidence of hyperthyroidism in the Veneto Region (Italy) over the period 2013-2022.
Retrospective population-based study conducted in Veneto (4.9 million people) using the population registry, an administrative health database. Between 2012 and 2022, hyperthyroidism incidence was defined thank to a health-care co-payment exemption for hyperthyroidism or any hospital diagnosis of hyperthyroidism. Incident hyperthyroidism was defined from 2013 to 2022 to exclude prevalent cases. Standardized incidence rates (IRs) were reported by age, sex, and etiology of thyroid hyperfunction too.
We identified 26,602 incident cases (IR of 54.38 per 100,000 person-years, 2.47-fold higher in females than in males). IR decreased from 69.87 (95% CI: 67.49, 72.25) in 2013 to 42.83 (95% CI: 40.99, 44.66) in 2022. In 2020, an out-of-trend decrease in hyperthyroidism incidence was documented, corresponding to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic outbreak, with a realignment to the trend in the subsequent years. The annual percentage change according to the cause of hyperthyroidism was as follows: -6.62% (95% CI: 8.47, 4.73) (P < 0.0001) in toxic multinodular goiter, -7.56% in toxic uninodular goiter (95% CI: 10.54, 4.48) (P < 0.001) and -4.70% (95% CI: 6.33, 3.04) in toxic diffuse goiter (Graves' disease) (P < 0.001).
We documented a decline in the incidence of hyperthyroidism in Veneto Region, paralleling the improvement of the iodine status, thanks to a long and sustained iodine prophylaxis campaign. SARS-CoV-2 pandemic and vaccination campaign did not change the declining trend of hyperthyroidism incidence in our study region.
An improvement in iodine status in the population residing in the Veneto region has been documented in the last decade, thanks to a nationwide voluntary iodine prophylaxis program running since 2005, but its impact on the epidemiology of thyroid disease has never been documented. This is the largest study on the incidence rates of hyperthyroidism carried out in Italy and covers the longest observation period among all regionwide population-based studies of hyperthyroidism in our country. We documented a reduction in the incidence of hyperthyroidism, which was more pronounced in nodular goiter diagnosis but involved also toxic diffuse goiter. The decline in the incidence of hyperthyroidism in Veneto Region shows the efficacy and safety of the iodine prophylaxis campaign.
过去十年间,威尼托地区的碘营养状况已有改善记录。我们旨在估算2013年至2022年期间意大利威尼托地区甲状腺功能亢进症的发病率。
利用人口登记册(一个行政卫生数据库)在威尼托地区(490万人)开展基于人群的回顾性研究。2012年至2022年期间,甲状腺功能亢进症发病率的定义依据甲状腺功能亢进症的医保费用豁免情况或任何医院作出的甲状腺功能亢进症诊断。2013年至2022年期间定义了新发甲状腺功能亢进症病例以排除现患病例。还按年龄、性别和甲状腺功能亢进病因报告了标准化发病率(IR)。
我们识别出26,602例新发病例(每10万人年的发病率为54.38,女性发病率是男性的2.47倍)。发病率从2013年的69.87(95%可信区间:67.49, 72.25)降至2022年的42.83(95%可信区间:40.99, 44.66)。2020年,记录到甲状腺功能亢进症发病率出现与趋势不符的下降,这与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)大流行暴发相对应,随后几年又恢复到原有趋势。按甲状腺功能亢进病因划分的年变化百分比如下:毒性多结节性甲状腺肿为-6.62%(95%可信区间:8.47, 4.73)(P<0.0001),毒性单结节性甲状腺肿为-7.56%(95%可信区间:10.54, 4.48)(P<0.001),毒性弥漫性甲状腺肿(格雷夫斯病)为-4.70%(95%可信区间:6.33, 3.04)(P<0.001)。
由于长期持续的碘预防活动,我们记录到威尼托地区甲状腺功能亢进症发病率下降,这与碘营养状况的改善相平行。在我们的研究地区,SARS-CoV-2大流行和疫苗接种活动并未改变甲状腺功能亢进症发病率的下降趋势。
过去十年间,由于自2005年起实施的全国性自愿碘预防计划,居住在威尼托地区人群的碘营养状况已有改善记录,但此前从未记录其对甲状腺疾病流行病学的影响。这是意大利开展的关于甲状腺功能亢进症发病率的最大规模研究,且在我国所有基于地区人群的甲状腺功能亢进症研究中观察期最长。我们记录到甲状腺功能亢进症发病率降低,在结节性甲状腺肿诊断中更为明显,但毒性弥漫性甲状腺肿也有下降。威尼托地区甲状腺功能亢进症发病率的下降表明碘预防活动的有效性和安全性。